You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,580,787


✉ Email this page to a colleague

« Back to Dashboard


Title:Compositions and methods for reducing activation of alpha-1 receptors
Abstract: The invention generally relates to compositions and methods for reducing activation of a-1 adrenergic receptors. The compositions comprise highly selective a-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Inventor(s): Horn; Gerald (Deerfield, IL)
Assignee: Eye Therapies LLC (Dana Point, CA)
Filing Date:Jul 27, 2009
Application Number:12/460,968
Claims:1. A method of scleral whitening without significant side effects of eye redness and/or rebound hyperemia comprising administering to a patient in need thereof an ocular drop consisting essentially of brimonidine, or a pharmaceutically acceptable salt thereof, wherein said brimonidine is present at a concentration of about 0.05% weight by volume or below.

2. The method of claim 1, wherein said brimonidine is present at a concentration between about 0.001% to about 0.025% weight by volume.

3. A method of scleral whitening without significant side effects of eye redness and/or rebound hyperemia comprising topically administering to a patient in need thereof an ocular drop consisting essentially of brimonidine into ocular tissue, wherein pH of said composition is between about 5.5 and about 6.5, wherein said brimonidine concentration is between about 0.001% and about 0.025% weight by volume.

4. The method of claim 3, wherein said composition is topically administered within about 24 hours after a Lasik surgery on said patient.

5. A method of scleral whitening without significant side effects of eye redness and/or rebound hyperemia comprising administering to a patient in need thereof brimonidine, or a pharmaceutically acceptable salt thereof, wherein said brimonidine is present at a concentration below about 0.05% weight by volume, wherein pH of said brimonidine is between about 5.5 and about 6.5, wherein said brimonidine is formulated as an ocular drop.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.